Article > US biopharma: 452 drugs for rare diseases now in R&D

US biopharmaceutical research companies are currently developing 452 new medicines for the treatment of rare diseases, according to new industry figures.

The 452 new medicines and vaccines, all of which are now in human clinical trials or under review by the Food and Drug Administration (FDA), include treatments for genetic disorders, neurological conditions, infectious diseases and autoimmune disorders, says the report, from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Although a rare disease is defined as one that affects fewer than 200,000 people in the US, the number of such conditions totals approximately 7,000 and collectively they affect nearly 30 million Americans, or one in 10 of the population, says PhRMA. According to the FDA, one third of all new drug approvals over the last five years have been for rare diseases.

Read the source article at PharmaTimes

About the Author

Leave a Reply